XIII Annual Congress of AMHH (Madrid Association of Hematology and Hemotherapy)
April 4th, 5th and 6th, 2018
ONCOCHECK includes six clinical trials involving children and adults suffering from solid or hematological tumors. Biological samples from over 5,000 participating subjects, half of them from cancer patients and the other half obtained from aged-pared controls, will be obtained to evaluate the role of Telomere Associated Variables (TAV) in cancer. Life Length, the leading global healthcare company in the field of telomere diagnostics, is the sponsor of these clinical studies, carried out in partnership with 32 Spanish hospitals.
For this reason, as we announced last June, Life Length and the AMHH, a non-profit organization whose main activity is cooperation to achieve scientific progress in medical disciplines, signed a partnership agreement related to Chronic Lymphocytic Leukemia (CLL) patients.
On Wednesday starts the 13th edition of the AMHH (Madrid Association of Hematology and Hemotherapy) Congress. It will let hematology professionals meet and share the latest innovations in the field, welcoming also some of the main health related companies.
This year the symposia are devoted to the cytological and molecular diagnosis and treatments of myelodysplastic syndromes and leukemias. The ONCOCHECK team will be attending the event, always aiming to achieve better cancer monitoring through innovative molecular solutions.
Follow us on Twitter to keep updated @oncocheck #AMHH #CLL